Chronic Hepatitis B InfectionPhase 1NCT07342881
Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
A Phase 1 study testing Pevifoscorvir Sodium (ALG-000184) in people with Chronic Hepatitis B Infection, run by Aligos Therapeutics at 2 sites in United States.
Trial summary
This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment (Optional Part 2) and in participants without renal impairment (Parts 1 and 2), matched for… Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Chronic Hepatitis B Infection
- What is being tested?
- Pevifoscorvir Sodium (ALG-000184)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 2 sitesUnited States
- Study dates
- 10 Mar 2026to 29 Jul 2026
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Male and Female between 18 and 75 years old
- Body Mass Index (BMI) 17.5 to 40.0 kg/m^2 and a total body weight >50 kg (110 lb)
- Female subjects must either be not of childbearing potential or if they are a woman of childbearing potential, they are only eligible if they and any non-sterile, male sexual partners agree to use highly effective contraceptive therapy
- Good general health as defined by no clinically relevant abnormalities identified by Medical History and a vital signs, clinical laboratory and 12-lead electrocardiogram (ECG) assessment
- Subjects must fit the demographic-matching criteria including body weight, age, and to the extent possible, sex
- Normal renal function (estimated Glomerular Filtration Rate [eGFR] ≥90 mL/min) with no known or suspected renal impairment
Show all 11Show fewer
- Inclusion Criteria for Subjects with Impaired Renal Function:
- Subject satisfies the eGFR criteria for renal impairment classification within 28 days of study drug administration
- Any form of renal impairment except acute nephritic syndrome (subjects with history of previous nephritic syndrome but in remission can be included).
- Stable concomitant medications for the management of an individual subject's medical history for at least 28 days prior to screening
- Subjects must have a 12-lead ECG and vital signs assessment that meet the protocol criteria
Who cannot join
- Subjects with any current or previous illness that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject or that could prevent, limit, or confound the protocol specified assessments or study results and interpretation
- Subjects with a past history of cardiac arrhythmias, risk factors for Torsade de Pointes syndrome (e.g., hypokalemia, family history of long QT Syndrome) or recent history or clinical evidence at screening of significant (subjects with normal renal function) or unstable (subjects with renal impairment) cardiac disease etc.
- Subjects with a history of clinically significant drug allergy
- Subjects with a recent (within 1 year of randomization) history or current evidence of drug abuse or recreational drug use
- Excessive use of alcohol defined as regular consumption of ≥14 units/ week for women and ≥21 units/week for men
- Unwilling to abstain from alcohol use for 48 hours prior to start of the study through end of study follow up
Show all 14Show fewer
- Subjects with Hepatitis A, B, C, E or HIV-1/HIV-2 infection or acute infections such as SARS- CoV-2 infection
- Subjects with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values >2x upper limit of normal (ULN)
- Subjects with bilirubin (total, direct) >1.5x ULN (unless Gilbert's is suspected)
- Positive pregnancy test; females must not be pregnant at enrollment
- 1. Hemoglobin <10 g/dL
- Exclusion Criteria for Subjects with Impaired Renal Function:
- Participants requiring hemodialysis and/or peritoneal dialysis
- Hemoglobin <9 g/dL
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Orlando Clinical Research Center
Orlando, Florida, 32809
Genesis Clinical Trials
Tampa, Florida, 33603
About this study
Official title: A Phase 1 Non-Randomized, Open-Label, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment (Optional Part 2) and in participants without renal impairment (Parts 1 and 2), matched for age, body weight and, to the extent possible, for sex.
- Conditions
- Chronic Hepatitis B Infection
- Being tested
- Pevifoscorvir Sodium (ALG-000184)
- Keywords
- Chronic Hepatitis B Infection
- Medical subject headings
- Hepatitis B, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pevifoscorvir Sodium (ALG-000184)Drug
Pevifoscorvir Sodium (ALG-000184) Single oral doses of 100 mg pevifoscorvir sodium
| Study group | Role | What they receive |
|---|---|---|
| Subjects with renal Impairment | Experimental | Subjects with renal impairment will receive single oral doses of 100 mg pevifoscorvir sodium. Subjects will be followed up for 14 days after the administration of study drug. Receives: Drug: Pevifoscorvir Sodium (ALG-000184) |
| Subjects without renal impairment | Experimental | Subjects without renal impairment will receive single oral doses of 100 mg pevifoscorvir sodium. Subjects will be followed up for 14 days after the administration of study drug. Receives: Drug: Pevifoscorvir Sodium (ALG-000184) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Area under the concentration time curve [AUC]
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Measured: Up to 4 days
Maximum plasma concentration [Cmax]
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Measured: Up to 4 Days
Minimum plasma concentration [Cmin]
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Measured: Up to 4 Days
C0 [predose]
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Measured: Up to 4 days
Half-life [t1/2]
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Measured: Up to 4 Days
Time to maximum plasma concentration [Tmax]
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Measured: Up to 4 Days
Apparent Clearance (CL/F)
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Measured: Up to 4 Days
Apparent Volume of Distribution (V/F)
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Measured: Up to 4 Days
Total Amount of Drug Excreted in Urine (Ae)
Urine PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Measured: Up to 4 Days
Renal Clearance (CLr)
Urine PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Measured: Up to 4 Days
Secondary outcomes (1)
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
The number and severity of treatment emergent events in subjects with renal impairment and subjects with normal renal function as assessed by DAIDS v2.1
Measured: Up to 15 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jan 2026
- Study start10 Mar 2026
- Primary completion29 Jul 2026
- Study completion29 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Hepatitis B InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment (Optional Part 2) and in participants without renal impairment (Parts 1 and 2), matched for age, body weight and, to the extent possible, for sex.
- Masking
- None (open label)
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- Aligos Therapeutics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07342881
- Sponsor's protocol ID
- ALG-000184-208
- Status last verified
- Aug 2026
- First submitted
- 15 Dec 2025
- Last updated
- 21 Aug 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1 Non-Randomized, Open-Label, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
- ClinicalTrials.gov ID
- NCT07342881
- Acronym / sponsor ID
- ALG-000184-208
- Conditions
- Chronic Hepatitis B Infection
- Keywords
- Chronic Hepatitis B Infection
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 12 participants (actual)
- Lead sponsor
- Aligos TherapeuticsIndustry (pharma, biotech, devices)
- Study start
- 10 Mar 2026 (actual)
- Primary completion
- 29 Jul 2026 (actual)
- Study completion
- 29 Jul 2026 (actual)
- First posted
- 15 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment (Optional Part 2) and in participants without renal impairment (Parts 1 and 2), matched for age, body weight and, to the extent possible, for sex.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment (Optional Part 2) and in participants without renal impairment (Parts 1 and 2), matched for age, body weight and, to the extent possible, for sex.
| Arm | Type | Receives |
|---|---|---|
| Subjects with renal Impairment | Experimental | Drug: Pevifoscorvir Sodium (ALG-000184)Subjects with renal impairment will receive single oral doses of 100 mg pevifoscorvir sodium. Subjects will be followed up for 14 days after the administration of study drug. |
| Subjects without renal impairment | Experimental | Drug: Pevifoscorvir Sodium (ALG-000184)Subjects without renal impairment will receive single oral doses of 100 mg pevifoscorvir sodium. Subjects will be followed up for 14 days after the administration of study drug. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Male and Female between 18 and 75 years old
- Body Mass Index (BMI) 17.5 to 40.0 kg/m^2 and a total body weight >50 kg (110 lb)
- Female subjects must either be not of childbearing potential or if they are a woman of childbearing potential, they are only eligible if they and any non-sterile, male sexual partners agree to use highly effective contraceptive therapy
- Good general health as defined by no clinically relevant abnormalities identified by Medical History and a vital signs, clinical laboratory and 12-lead electrocardiogram (ECG) assessment
- Subjects must fit the demographic-matching criteria including body weight, age, and to the extent possible, sex
Key exclusion criteria (14 listed)
- Subjects with any current or previous illness that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject or that could prevent, limit, or confound the protocol specified assessments or study results and interpretation
- Subjects with a past history of cardiac arrhythmias, risk factors for Torsade de Pointes syndrome (e.g., hypokalemia, family history of long QT Syndrome) or recent history or clinical evidence at screening of significant (subjects with normal renal function) or unstable (subjects with renal impairment) cardiac disease etc.
- Subjects with a history of clinically significant drug allergy
- Subjects with a recent (within 1 year of randomization) history or current evidence of drug abuse or recreational drug use
- Excessive use of alcohol defined as regular consumption of ≥14 units/ week for women and ≥21 units/week for men
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pevifoscorvir Sodium (ALG-000184)Pevifoscorvir Sodium (ALG-000184) Single oral doses of 100 mg pevifoscorvir sodium | Drug | Subjects with renal Impairment, Subjects without renal impairment |
Primary outcome
Area under the concentration time curve [AUC]
Time frame: Up to 4 days
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Maximum plasma concentration [Cmax]
Time frame: Up to 4 Days
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Minimum plasma concentration [Cmin]
Time frame: Up to 4 Days
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
C0 [predose]
Time frame: Up to 4 days
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Half-life [t1/2]
Time frame: Up to 4 Days
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Time to maximum plasma concentration [Tmax]
Time frame: Up to 4 Days
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Apparent Clearance (CL/F)
Time frame: Up to 4 Days
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Apparent Volume of Distribution (V/F)
Time frame: Up to 4 Days
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Total Amount of Drug Excreted in Urine (Ae)
Time frame: Up to 4 Days
Urine PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Renal Clearance (CLr)
Time frame: Up to 4 Days
Urine PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
1 secondary outcome
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time frame: Up to 15 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2026.
Related trials for Chronic Hepatitis B Infection
RecruitingObservational study
Evaluation of Patients With Liver Disease
Hepatitis D, Hepatitis C
RecruitingPhase 2
A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
Chronic Hepatitis B Virus (HBV) Infection
RecruitingObservational study
"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
Chronic Liver Disease and Cirrhosis, Liver Cancer
Not yet recruitingPhase 1
A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) Participants
Chronic Hepatitis B Virus
Not yet recruitingPhase 1/2
A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)
Chronic Hepatitis B
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Pevifoscorvir Sodium (ALG-000184) in people with Chronic Hepatitis B Infection, run by Aligos Therapeutics at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Area under the concentration time curve [AUC] (time frame: Up to 4 days). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2026.